Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors

NCT07661797 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

294

Enrollment

INDUSTRY

Sponsor class

Conditions

Patients With Advanced Solid Tumors

Interventions

DRUG: LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4)

Sponsor

Shandong New Time Pharmaceutical Co., LTD